Canaccord Genuity Lists Medtech Firms Most Likely to Be Acquired

AtriCure Business for surgical ablation specialist AtriCure has been good lately. Last month, MedCity News ran an article suggesting that the company could be attractive to medtech giants such as Medtronic, St. Jude In a message to investors, Mills explains that Canaccord Genuity likes “the company’s leadership position in the surgical atrial fibrillation market currently” as well as “the company’s new product and clinical trial pipeline.“

HeartWare Things are looking up for left ventricular assist device (LVAD) maker HeartWare. In Forbes’ estimation, the company is a “burgeoning LVAD player.” In addition, the company recently reported that it had promising clinical data for its new ventricular assist system at the European Association for Cardio-Thoracic Surgery in Lisbon, Portugal.

Spectranetics Cardiovascular technology maker Spetranetics has what Forbes terms an “attractive lead management business.” The company was recently named to a list of “10 Undervalued Stocks.” Mills explains that Canaccord Genuity believes the company’s “lead management business is worth the stock’s current valuation on its own,” owing to the firm’s growth profile, high barriers to entry, and other factors.

Thoratec Like HeartWare, Thoratec specializes in the production of LVADs and other devices for circulatory support. Its stock recently reached a 52-week high.

Volcano Volcano Corp. is a company specializing in intravascular ultrasound and heart diagnostic technology that had fallen on hard times a couple of years ago but began rebounding around the beginning of 2010. The company, which has a strong presence in Japan, has fared well despite the quake and tsunami in that country earlier this year.